New England Research & Management Inc. Has $964,000 Stock Position in Danaher Co. (NYSE:DHR)

New England Research & Management Inc. reduced its stake in shares of Danaher Co. (NYSE:DHR) by 1.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,860 shares of the conglomerate’s stock after selling 50 shares during the period. New England Research & Management Inc.’s holdings in Danaher were worth $964,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of DHR. ST Germain D J Co. Inc. raised its holdings in shares of Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the last quarter. Nicholas Hoffman & Company LLC. grew its stake in shares of Danaher by 2.3% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after buying an additional 43 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Danaher by 1.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares in the last quarter. Berger Financial Group Inc grew its stake in shares of Danaher by 1.7% in the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after buying an additional 43 shares in the last quarter. Finally, Pinnacle Wealth Planning Services Inc. grew its stake in shares of Danaher by 1.0% in the fourth quarter. Pinnacle Wealth Planning Services Inc. now owns 4,329 shares of the conglomerate’s stock valued at $1,001,000 after buying an additional 43 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 0.7 %

Shares of Danaher stock opened at $250.03 on Friday. The firm has a 50-day moving average of $255.96 and a 200-day moving average of $246.43. The stock has a market cap of $185.19 billion, a PE ratio of 42.38, a PEG ratio of 3.85 and a beta of 0.85. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $269.11. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.36 earnings per share. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Citigroup raised their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Robert W. Baird lifted their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $269.29.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock valued at $37,536,717 over the last quarter. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.